

































































and	 the	 special	 certificate	 for	pharmaceuticals,	 the	 supplementary	protection	 certifi-
cate.	Moreover,	the	economical	and	technological	use	of	pharmaceutical	patents	will	
also	 be	 discussed.	 The	 interaction	 of	 archetypes	 and	 generics	 in	 the	 pharmaceutical	
industry	affects	this	 industry	through	aspects	such	as	competition,	parallel	 import,	 li-
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Introduction	
Intellectual	 Property	 Law	 is	 the	 area	 of	 law	 that	 concerns	 legal	 rights	 that	 associate	
with	 creative	 effort	 or	 commercial	 reputation.1	 There	 are	many	 reasons	 behind	 the	
existence	of	Intellectual	Property.	Some	of	them	are	the	encouragement	of	innovation,	


























1977	 and	 applicants	 could	 then	 file	 a	 single	 patent	 application	with	 the	 EPO	 that,	 if	
granted,	was	applicable	in	all	the	member	–	States	that	the	claimant	chose.10	Inventors	
can	also	file	a	claim	to	the	World	Intellectual	Property	Organization	(WIPO)	in	order	to	
request	 the	grant	of	national	patents	 in	any	 country	 that	 is	 a	member	 in	 the	Patent	
Cooperation	 Treaty	 (PCT).	 This	 method	 is	 quicker	 and	 can	 provide	 multiple	 patents	
granted	 in	different	countries	with	only	one	application.11	After	the	expiry	of	 the	pa-
tent,	the	invention	falls	into	the	public	domain,	where	everyone	can	use	it.	











pharmaceutical	companies	to	protect	their	 innovative	 inventions.	 In	pharmaceuticals,	
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law	 in	 the	E.U.	 interacts	with	pharmaceutical	patents,	 since	 their	existence	seems	 to	


















concerning	“medicines”.	Medicine	 is	 a	product	 that	has	 special	physical	 capacity	and	
consists	 various	 ingredients	 in	 specific	 quantities	 that	 follow	 a	 specific	 procedure.	 A	
medicine	 is	 considered	 to	 become	 a	 pharmaceutical	 product	 from	 the	moment	 it	 is	
produced	in	a	massive	quantity.12	When	a	medicine	is	first	developed	by	a	pharmaceu-
tical	company,	it	is	sold	under	this	company’s	brand	name	and	it	is	protected	by	patent	
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After	the	implementation	of	paragraph	6	of	the	Doha	Declaration	on	the	TRIPs	Agree-
ment	and	public	health	in	2003,	a	new	definition	concerning	medicines	started	to	exist.	











a	medical	diagnosis	or	 to	 restoring,	correcting	or	modifying	physiological	 functions	 in	
human	beings	is	likewise	considered	a	medicinal	product.”17	There	are	also	more	defi-
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GENERIC	MEDICINES	
Another	 category	of	medicines,	which	 is	 also	well	 –	 known,	 is	 this	 of	“generic	medi-
cines”	or	“generics”.	A	generic	medicine	is	identical	or	bioequivalent	to	a	brand	name	
one	 in	 dosage	 form,	 safety,	 strength,	 route	 of	 administration,	 quality,	 performance	






really	expensive	and	can	bring	a	 lot	of	profit	 to	pharmaceutical	 companies	 that	own	
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ii. The	pharmaceutical	 company	 that	produces	a	generic	proves	 that	 there	 is	no	
infringement	 as	 regards	 the	 generic	 and	 the	 prototype’s	 patent	 or	 that	 the	
pharmaceutical	patent	is	null	and	void.	
iii. The	archetype	medicine	was	never	protected	by	a	patent.	
iv. The	archetype	medicine	 is	not	protected	by	patent	 law	 in	 the	 country	where	
the	generic	is	produced.22	












the	 pharmaceutical	 market	 with	 the	 International	 Non	 –	 proprietary	 Name	
(INN)	of	 its	active	chemical	 substance	and	 is	defined	by	 the	World	Health	Or-
ganization	(WHO).23		
ii. The	“brand”	generics.	These	generics	are	circulated	in	the	pharmaceutical	mar-
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iii. The	“copy	products”.	 The	copy	products	have	a	main	difference	compared	 to	
other	generics.	 They	 tend	 to	 copy	a	prototype	medicine	 for	which	a	pharma-




































































of	 generics	 are	 that	 first,	 generics	 are	 for	 patients	 and	 can	 create	 a	 better-value	
healthcare.	 Second,	 generics	 stand	 for	 quality,	 since	 in	 order	 to	 be	 released	 to	 the	
market	they	have	to	be	approved	and	tested	really	strictly,	according	to	E.U.	and	na-










companies	 for	 the	 enhance	 of	 research	 to	 create	more	medicines	 and	 improve	 the	
ones	that	already	exist.	Is	it	safe	to	decrease	their	profit	in	such	an	amount	that	further	
research	would	then	be	impossible?	A	prototype	drug	is	the	result	of	years	of	studies,	
research	 and	 money	 spent	 by	 scientists	 and	 pharmaceutical	 companies.	 However,	
there	are	incidents	where	a	pharmaceutical	company	tries	to	secure	profit	by	misusing	
pharmaceutical	patents.		
In	my	 opinion,	 the	 promotion	 of	 generics	 is	 vital	 for	 the	 limitation	 of	monopoly.	 Of	
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protected	both	economically	and	technologically.	That	is	why	pharmaceutical	patents	
exist.	 Inside	a	market,	 the	stronger	part	cannot	be	equipped	with	all	 the	means	 that	
protect	itself	against	the	weaker	one.	It	is	fair	enough	that	balance	is	provided,	so	that	
both	parties	have	equal	protection	and	opportunities	for	profit.	Since	pharmaceutical	




the	 generics	 pharmaceutical	 companies.	 Both	 these	 kinds	 of	 companies	 should	 exist	
for	a	healthy	and	fair	pharmaceutical	market	to	exist	and	flourish.	The	WHO	has	stated	
that	“Competition	is	the	most	powerful	mean	of	politics	used	to	decrease	the	price	of	
medicines	 that	 their	 patents	 have	 expired…”.33
																																																						
33	(Καφετζής,	2013)	pp.	122-123.		
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PATENTS	AND	PHARMACEUTICAL	INDUSTRY	
The	American	virologist	 Jonas	Edward	Salk had	 to	work	 really	hard	 for	almost	 seven	
years	in order	to	discover	the	vaccine	that	can	cure poliomyelitis.	After	World	War	II	
(W.W.II),	polio	was	number	one threat	for	mankind,	since	in	1952,	in	the	U.S.,	58,000	









Pharmaceutical	patents	are	more	complicated	than	the	other	ones.	That	 is	 logical,	 in	
my	opinion,	considered	that	medicines	are	not	simple	chemical	products,	but,	on	the	
contrary,	they	involve	more	than	one	substances	and	procedures	used	to	manufacture	
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i. The	“composition	patent”	(product	patent).	This	patent	is	the	strongest	one	and	
protects	 the	actual	active	chemical	
substance	 in	 a	 medicine.	 Once	 a	
medicine	 is	protected	by	a	compo-
sition	patent,	no	other	pharmaceu-
tical	 company	 is	 able	 to	 produce,	
sell	 or	 import	 that	 chemical	 sub-
stance.	 If	that	happens,	 it	 is	clearly	
and	 infringement	 of	 the	 patent	
right.35				




ready	 protected	 medicine.36	 This	
kind	 of	 right	 can	 be	 protected	 in	
some	 countries,	 such	 as	 the	 U.S.	




iv. The	“process	patent”.	 This	patent	protects	 the	chemical	or	any	other	process	












  -17- 
pharmaceutical	 company	 has	 been	 using	 a	 patent	 protected	 process,	 many	
countries	have	 legislation	that	provides	a	reversed	burden	of	proof.	Thus,	 the	
company	accused	of	being	 infringing	a	patent	 is	 the	one	responsible	to	prove	
that	such	an	infringement	does	not	actually	exist.39	
v. The	“evergreening	patent”.	This	kind	of	patent	is	granted	to	improved	or	modi-
fied	 medicines	 that	 have	 been	 already	 protected.40	 There	 are	 arguments	
against	the	existence	of	such	patents,	since	the	pharmaceutical	companies	try	
to	 gain	 more	 time	 of	 protection	 by	 producing	 small	 and	 of	 minimum	 im-
portance	changes	to	their	medicines.	A	well-known	example	of	this	kind	of	dis-
pute	 is	 the	Novartis	 v.	 Union	 of	 India	 and	 Others	 case,	 which	was	 finally	 re-
solved	in	2013	by	the	Supreme	Court	of	India.41	According	to	the	judgment,	the	
Court	has	decided	that	the	anti-	cancer	Novartis’s	medicine	“Glivec”	is	not	pro-
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The	scope	of	the	SPC	is	not	to	extend	the	entire	pharmaceutical	patent,	but	to	preserve	
the	 protection	 given	 to	 the	 product	 covered	 by	 the	 marketing	 authorization.48	 The	
Regulation	tries	to	put	some	quality	and	quantity	limits	regarding	the	SPC.49	The	sales	
of	 the	product	 for	non-medical	use	 is	not	an	 infringement.50	The	subject	–	matter	of	
the	SPC	is	the	“product”;	the	“active	ingredient	or	combination	of	active	ingredients	of	







pharmaceutical	SPC	 is	 interpreted	according	to	the	 latter	Regulation,	then	whether	a	
granted	pharmaceutical	 patent	 covers	 also	other	 forms	of	 the	product,	 the	 SPC	 also	
covers	them,	even	 if	 the	marketing	authorizations	was	for	only	one	form.53	This	 is	of	
great	 importance,	 since	 it	 clears	 all	 the	uncertainty	 that	discouraged	pharmaceutical	
companies	from	applying	for	an	SPC	and	promotes	its	existence.	
Moreover,	 a	 decision	made	 by	 the	 European	 Court	 of	 Justice	 (ECJ)	 has	widened	 the	
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industry	 begun	 to	 exist	 during	
the	 end	 of	 the	 19th	 century,	
when	 scientists	 discovered	 that	
some	raw	materials	had	antisep-








One	 of	 the	 reasons	 behind	 the	
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tect	the	extensive	investment	in	research	and	clinical	testing	required	before	placing	it	
on	the	market.56	It	is	thought	that,	for	the	creation	of	a	new	and	successful	medicine,	
scientists	 need	 to	 spend	 approximately	 10	 to	 15	 years	 for	 studies,	 research,	 clinical	
tests,	price	 fixation	etc.57	 (Figure	 3:	 Phases	 of	 a	medicine's	 production).	During	 these	years,	












that,	 technological	 information	 is	 spread	 to	 others	 and	 so	 does	 knowledge	 and	 the	
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compared	to	other	industries,	because	the	actual	manufacturing	process	is	often	easy	
to	replicate	and	can	be	copied	with	a	 fraction	of	 the	 investment	of	 that	 required	 for	
the	research	and	clinical	testing.	A	medicine,	of	course,	cannot	be	protected	forever.	
After	the	expiry	of	the	patent,	the	medicine	falls	into	the	public	domain	and	everyone	






courages	new	 investors	 from	offering	money	 to	 innovation	 and	new	 research	 in	 the	





tical	 companies	 and	 so	 many	 European	 companies	 tend	 to	 transfer	 to	 the	 United	
States	(U.S.),	since	they	provide	a	friendly	environment	that	welcomes	companies	and	
their	investments.62	
Patents	 in	 the	pharmaceutical	 industry	are	 trying	 to	 reverse	 this,	 since	 they	give	 the	












dustries	 and	 Associations	 (EFPIA)	 report,	 27	million	 euros	 were	 spent	 in	 the	 E.U.	 in	
2010	 in	 the	departments	of	 research	and	development	of	 the	pharmaceutical	 indus-
try.63	It	is	essential	to	mention	that	no	pharmaceutical	product	is	allowed	to	be	circu-
lated	 in	 the	 European	 pharmaceutical	 market	 unless	 a	 marketing	 authorization	 has	
been	first	granted	(article	3(1)	Regulation	726/2004).64		
THE	PHARMACEUTICAL	MARKET	
Pharmaceutical	 market	 seems	 to	
behave	 differently	 compared	 to	
other	markets	(Figure	4:	The	European	
Pharmaceutical	 Industry).	 One	 of	 the	
reasons	 behind	 this	 conclusion	 is	
the	 fact	 that	 it	 is	 characterized	by	
some	 special	 features	 which	 are	





distinguishes	 it	 from	 all	 the	 other	
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ion,	the	almost	full	separation	between	consumers	and	purchasers	of	the	product.66		
PHARMACEUTICAL	MARKET’S	CHARACTERISTICS	
First	 of	 all,	pharmaceutical	market	 is	 a	 part	 of	 the	 healthcare	market	 which	 is	 con-
trolled	by	“information	asymmetry”.	By	this	term,	it	is	meant	that,	most	of	the	times,	





not	 the	ones	 in	 charge.	On	 the	 contrary,	 the	 leader	 seems	 to	be	 the	medical	practi-
tioner	–	producer,	who	prescribes	 the	appropriate	medicine	needed	for	a	cure	to	be	
achieved	 (“consumer	 sovereignty”).	 Because	of	 this	 gap	 that	 exists	 between	patients	





Secondly,	 there	 is	 also	 the	 “moral	 hazard”.	 The	 insurance	 company	 or	 organization,	
according	to	each	country’s	legislation,	is	obliged	to	return	to	the	patient	the	economic	
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vaccination	for	the	prevent	of	an	epidemic	is	an	externality	that	can	protect	a	person	
from	getting	sick	or	from	transmitting	a	disease	to	another	person.68	
In	 my	 opinion,	 these	 characteristics	 are	 the	 main	 reason	 behind	 the	 failure	 of	
healthcare	market	as	 it	 is	structured	and	the	reason	why	the	right	 in	health	must	be	
treated	as	a	free	and	public	right.			
DEMAND	AND	OFFER	IN	THE	PHARMACEUTICAL	MARKET	
It	 is	already	mentioned	 that	 in	 the	pharmaceutical	market	 the	patient	–	consumer	 is	
not	 the	one	who	 takes	 the	decision	 concerning	 the	 choice	 of	medicines.	Demand	 in	
pharmaceutical	market	is	not	estimated	only	by	consumers,	but	by	many	factors.	Med-
ical	practitioners,	insurance	organizations,	pharmacists	and	the	patient	interact.	69		As	a	
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This	is	also	boosted	by	these	facts.	Consumption,	thus	demand,	in	the	pharmaceutical	
market	is	affected	by	five	factors:	




of	medicines	 for	 elderly	 people	who	need	 them	 in	 greater	 and	more	 specific	
amounts.	
iii. By	epidemiological	 factors,	 since	diseases	are	 the	main	cause	 that	pushes	pa-
tients	to	the	pharmaceutical	market.	






v. By	 healthcare	 factors.	 Nowadays,	more	 and	more	medical	 practitioners	 exist	
and	more	medicines,	 that	 cure	 illnesses	 that	 used	 to	 be	 fatal,	 appear.	 Thus,	
people	tend	to	care	more	about	their	health	and	their	treatment.71	
As	 far	as	offer	 is	 concerned,	 there	are	also	some	particularities.	The	main	one	 is	 the	
result	 of	monopoly	 that	 is	 granted	 to	 pharmaceutical	 companies	 by	 pharmaceutical	
patents.72	 It	becomes	clear,	more	 than	once,	 in	my	opinion,	 that	pharmaceutical	pa-
tents	do	not	only	grant	companies	with	rights	 that	make	them	feel	secure,	 they	also	
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The	main	characteristics,	that	adjust	offer	 in	the	pharmaceutical	market	are	the	ones	
mentioned	below:	




big	 multinational	 pharmaceutical	 companies,	 which,	 of	 course,	 are	 the	 most	
powerful	ones.	Second,	the	pharmaceutical	companies	that	are	capable	of	the	
produce	 of	 prototypes,	 but	 focus	 only	 in	 the	 produce	 of	 generics.	 Third,	 the	
pharmaceutical	 companies	 that	 operate	 in	 a	more	 “family	 business”	manner	
and	are	not	as	powerful	as	the	previous	ones.73	
To	 sum	 up,	according	 to	 the	WHO,	 the	adjustment	 of	 the	 pharmaceutical	market	 is	
characterized	by	 three	 facts.	 First,	by	 the	“product	 regulation”,	where	medicines	are	
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Greece	 is	 in	 economic	 depression,	 is	 not	 limited.	
Greek	 companies	 produce	 various	 generic	 medi-
cines	 that	 are	 exported	 to	 countries	 not	 only	 in	
Europe,	but	in	four	continents.	77	However,	Greek	
pharmaceutical	 companies	 do	 not	 only	 produce	
generics.	They	also	create	new	medicines.	(Figure	5:	
Example	of	Greek	Pharmaceutical	 Patent	Certificate).	 	For	
example,	 the	 Greek	 pharmaceutical	 company	
Elpen	has	a	very	strong	intellectual	proper-
ty	 portfolio.	 “Elpenhaler”,	 an	 inhaler	 de-
vice,	 has	 been	 granted	more	 than	 90	 pa-




and	UNI	 –	 PHARMA	 S.A.	 cannot	 be	 forgotten,	 since	 it	 is	 positive	 towards	 the	Greek	
pharmaceutical	company	and	analyzes	 in	depth	and	 in	a	correct	manner	 the	difficult	
issues	that	concern	medicines,	their	packages,	how	consumers	interact	with	the	view	




















can	 provide	 high	 profit	 due	 to	 their	 lower	 price	 and	 cost	 of	manufacture.80	 Generic	
medicines	enhance	competition,	since	they	are	cheaper	than	the	prototypes	but	have	
the	same	effects	as	them.	As	a	result	a	lot	of	people	prefer	to	purchase	them	instead	
of	 the	more	 expensive	 archetype	medicine.	 The	 E.U.	 also	 tries	 to	 promote	 generics	



















pharmaceutical	 market	 is	 in	 Europe	 and	 the	 U.S.	
(Figure	 6:	 The	World	 Pharmaceutical	 Industry	 (2010)).	 The	
U.S.	controls	the	38,1%	of	the	global	pharmaceuti-
cal	 market,	 Europe	 the	 36,1%,	 while	 Japan	 and	
other	countries	only	the	7,7%	and	18,1%.	Though	it	
seems	 like	 the	 U.S.	 pharmaceutical	 market	 has	
flourished	 during	 the	 last	 two	 decades	 (Figure	 7:	
Sales	 in	 the	 Pharmaceutical	 Market	 (2015)),	 since	 many	
companies	 were	 transferred	
there,	 on	 the	 contrary,	 the	
European	 pharmaceutical	
market’s	 production	 has	 in-




but	also	 to	make	enough	profit,	 so	 that	more	 research	and	development	 is	 inspired.	
The	definition	of	healthy,	fair	and	workable	competition	does	not	exist	in	the	Treaty	of	
Functioning	of	 the	European	Union	 (TFEU),	but	 can	be	concluded	by	 the	case	 law	of	
the	ECJ.	For	a	competition	to	be	effective	it	is	essential	that	the	market	is	structured	in	
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iii. “Innovative	efficiency”	(more	research).84		
	The	 EU	 is	 trying	 to	 accom-
plish	 this	 by	 many	 means.	
The	 first,	 and	 the	 most	 im-
portant	 one,	 in	 my	 opinion,	
is	the	harmonization	of	legis-
lation,	 concerning	 pharma-
ceutical	 patents	 and	 compe-
tition	 law,	 throughout	 the	
E.U.	member	 –	 States.	The	




recognizes	 a	 special	 privi-
lege	for	pharmaceutical	patents,	the	SPC.	The	third	is	that	E.U.	competition	law	strives	
to	promote	single	market	integration,	so	that	pharmaceutical	market	will	not	be	divid-
ed	 in	 national	 level.85	 Of	 course,	 the	 existence	 of	 harmonized	 legislation	 concerning	
patent	law	and	especially	pharmaceutical	law	is	also	the	key	behind	the	success	of	the	
above.	The	link	between	patents	and	competition	is,	nevertheless,	more	obvious	than	
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question	the	link	between	patents,	innovation	and	healthy	competition	in	the	field	of	
pharmaceutical	market.	They	claim	that	there	is	no	proof	of	a	link	between	them	and	
that	 pharmaceutical	 companies	 do	not	 focus	 on	 innovation	 and	 the	development	 of	
the	most	urgent	and	lifesaving	medicines,	but	on	the	development	of	the	most	profit-
able	 ones.	 It	 is	 true	 that	 in	 the	 U.S.	 pharmaceutical	 market	 the	 profit	 made	 of	 the	
blockbuster	medicines	 is	 immense.87	 Professor	 Sager	 has	 pointed	 out	 that	 since	 pa-
tents	 are	 extended	 and	 general,	 pharmaceutical	 companies	 are	 used	 to	 operate	 like	
monopolies.88		
An	 issue	 that	 enhances	 this	belief	 is	 that	of	“Daraprim”	medicine	 (U.S.).	Daraprim	 is	
used	by	people	that	are	infected	by	IHV,	produced	by	the	Turing	Pharmaceutical.	This	
medicine	 is	62	years	old	and	 is	used	against	 toxoplasmosis.	Unfortunately,	 the	phar-
maceutical	company	has	decided	to	increase	its	cost	from	13,50$	to	750$,	because	the	
previous	 price	 could	 not	 make	 enough	 profit	 for	 the	 company.	 Thus,	 in	 India	 a	 pill	
could	 cost	 around	 $0.05,	 in	 U.K.	 around	 $0.66,	while	 on	 the	 other	 hand	 in	 the	U.S.	
$750!	Even	 though	this	medicine	 is	not	protected	by	patent	 law,	 the	pharmaceutical	
company	has	indeed	a	great	monopoly	over	it,	since	other	pharmaceutical	companies	
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will	pharmaceutical	companies	be	able	 to	 invest	 into	research	and	medicines.	Other-
wise,	 high	 risk	 investments	 will	 discourage	 the	 fund	 owner’s.	 Balance	 between	 re-
search	and	 innovation	 in	medicines	and	 fair	 competition	will	be	destroyed	with	 fatal	
results	for	healthcare.	It	is	imperative	that	balance	is	the	beginning	and	the	end	of	eve-
ry	new	measure	taken	to	manage	the	pharmaceutical	market	and	its	areas	and	not	to	








i. The	 first	 type	 concerns	
the	phenomenon	of	par-
allel	 imports.	 According	
to	 it,	 a	medicine	 is	 pro-
duced	 in	 two	 or	 more	
different	 countries	 and	
is	 then	 sold	 in	 different	
“ex-factory	 prices”.	
Sometimes	 these	 facto-




tent.	The	medicine	 is	purchased	by	a	supplier	 in	a	country	with	 the	 lower	ex-
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ii. The	second	type	concerns	the	phenomenon	of	parallel	re-imports.	According	to	
it,	the	same	pharmaceutical	company	exports	a	medicine	in	a	lower	price	than	









point	 to	 a	more	 fair	 and	 healthy	 pharmaceutical	market.91	 A	market	 that	 seems,	 as	








tion	of	goods	and	services	 throughout	 the	E.U.	 It	 cannot	be	omitted	 that	one	of	 the	
fundamental	 objectives	 of	 the	 E.U.	 Treaty	 was	 the	 creation	 of	 a	 Common	 Market,	
where	goods	will	be	circulated	freely,	with	only	a	 few	exceptions.92	One	of	 these	ex-
ceptions	is	that	E.U.	law	seems	to	recognize	the	existence	of	patents	given	by	member	










An	 important	 case	 concerning	 the	 issue	of	 parallel	 import	 is	 the	Centrafarm	BV	and	
Adriaan	da	Peijper	v.	Sterling	Drug	INC	case.	The	Sterling	Drug	company	was	granted	
patents	 for	both	the	U.K.	and	Netherlands	regarding	a	medicine	against	urinary	tract	










it	did	so,	 it	would	cross	the	lines	of	free	movement	of	goods	 inside	the	E.E.A..94	As	 it	
can	 be	 concluded,	 the	 main	 criterion	 of	 whether	 parallel	 import	 is	 legal	 or	 illicit	 is	
whether	the	exhaustion	of	the	patent	right	has	occurred	in	the	E.E.A..95		
Although	to	some	it	may	seem	that	there	is	a	clash	between	competition	and	patents,	
the	 truth	 is	 that	patents,	 and	 generally	 intellectual	 property	 rights,	 promote	healthy	
competition	 and	 consumer’s	 welfare.	 Pharmaceutical	 patents	 are	 imperative,	 since	
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According	 to	 the	 ECJ,	 AstraZeneca	 has	 committed	 two	 abuses	 of	 dominance	 (Article	
102	TFEU)	of	 the	patent	system.	 It	has	made	“misleading	 representations”	of	certain	
dates	 to	national	patent	offices	 to	extent	 the	protection	granted	 to	one	of	 its	block-
buster	gastrointestinal	treatments	(“Losec”)	by	SPC.97	Moreover,	by	selective	deregis-
tration	of	 its	medicine’s	older	 form,	 it	has	not	allowed	pharmaceutical	 companies	 to	
obtain	 marketing	 authorization	 for	 their	 generics	 (Article	 4(3)(8)(a)(iii)	 Directive	
65/65).98	 AstraZeneca	 demanded	 the	 withdrawal	 of	 the	marketing	 authorizations	 in	
Denmark,	 Norway	 and	 Sweden.	 However,	 this	 action	 could	 result	 the	 restriction	 of	
parallel	import	of	the	products	to	these	countries.99	As	the	ECJ	stated,	a	dominant	un-
















alyze	 the	 pharmaceutical	 market	 and	 its	 complex	 structure.	 Last	 but	 not	 least,	 the	
competent	authorities	are	now	triggered	to	further	question	patent	procedures.103	
All	 these	consequences	are	of	equal	 importance,	but	 the	most	 important	one,	 in	my	
opinion,	is	the	first	one.	A	new	standard	was	created	as	regards	abuse	of	dominance,	a	
standard	that	is	about	to	change	the	way	pharmaceutical	market	works.	It	is	vital	that	
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THE	ISSUE	OF	“ACCESS	TO	MEDICINES”	
Two	main	issues	were	discussed	regarding	science,	legislation	and	case	law	of	pharma-
ceutical	 patents.	 The	 first	
one	concerns	the	legality	of	
their	 existence	 and	 the	 se-
cond	one	the	consequences	
of	 TRIPS	 Agreement.	 TRIPS	
Agreement	clearly	seems	to	
recognize	 the	 grant	 of	




economy	 and	 involves	many	 political,	 social,	 economical,	medical	 and	moral	 dimen-
sions	(Figure	9:	Pictures	used	by	WHO	for	access	to	medicines.).	Nowadays,	access	to	medicines	
is	becoming	a	priority	concern	both	for	developing	and	developed	countries.	The	high	
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it	will	respect	the	pharmaceutical	patent	of	another	and	would	seek	for	the	grant	of	a	
license.113		
Pharmaceutical	 patent	 licenses	 are	 the	 solution	 given	 to	 a	manufacturer,	 when	 the	














erning	 the	system	of	property	ownership».117	Thus,	 the	EU	 legislation	and	article	102	
TFEU	are	not	able	to	annul	patents.	To	solve	this	problem,	the	EU	case	law	developed	
















However,	 pharmaceutical	 companies	 seem	 to	 find	 several	 ways,	 sometimes	 even	 a	
combination	of	them,	to	protect	their	medicines	against	generics.	A	typical	example	is	
the	Perindopril	 case	 (2014).	According	 to	 the	Commission,	Les	Laboratories	Servier,	a	
French	pharmaceutical	company,	has	started	an	anti-generics	strategy	 from	1990s.	 It	
protected	 its	most	 popular	medicine,	 “Perindopril”,	 by	patents	 and	 reverse	payment	
























to	 pay	 any	 royalties	 owned.	 On	 the	 other	 hand,	 Genentech’s	 opinion	 was	 that	 this	
award	was	a	violation	of	Article	101	TFEU.	The	ECJ	stated	that	Article	101	TFEU	should	
not	be	interpreted	in	way	that	it	precludes	the	payment	of	royalties	provided	by	a	li-
cense	agreement,	even	 if	 the	same	agreement	provides	the	right	to	terminate	the	 li-
cense	by	a	reasonable	notice.123	
COMPULSORY	LISENCING	
The	definition	provided	by	the	WTO	states	 that	compulsory	 licensing	 is	when	a	State	
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However,	 TRIPS	 Agreement	 (article	 31)	 enlists	 conditions	 that	 define	 compulsory	 li-
censing.	First,	 that	the	one	interested	in	applying	for	compulsory	 license	should	have	
already	 tried	 to	negotiate	a	 voluntary	 license,	but	 in	 vain.	Although,	 if	 there	 is	 a	na-
tional	 emergency	 or	 an	 extreme	 urgency,	 the	 scale	 of	 the	 voluntary	 license	 can	 be	
skipped.	Second,	a	compulsory	license	does	not	eliminate	the	need	of	payment	of	roy-
alties	to	the	patent	owner.	Of	course,	compulsory	license	is	a	non-exclusive	one,	since	













ance	 the	situation,	 the	existence	of	pharmaceutical	patents	 is	 crucial.	However,	 they	
must	not	be	used	thoughtlessly.		
Between	 the	different	 types	of	medicines,	 the	one	 that	 causes	 the	more	disputes	 in	
the	pharmaceutical	industry	is	the	generic	one.	Generics	enhance	competition	and	are	
the	solution	to	the	problem	of	access	to	medicines,	however	the	one-sided	promotion	
of	 them	will	 destroy	 the	whole	pharmaceutical	market.	 Investors	will	 no	 longer	 give	
funds	 to	 innovative	 research	 and	 archetype	 companies	will	 be	 financially	 destroyed.	
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islators	to	create	new	and	more	efficient	legislation	that	can	both	control	pharmaceu-










a	 standard	 that	could	change	 the	way	pharmaceutical	market	works.	But	even	 if	 the	
grounds	of	accusing	a	company	for	an	abuse	are	lowered	by	this	ECJ	decision,	balance	
should	be	preserved.	This	decision	must	not	be	used	thoughtlessly	by	generics	compa-









people,	 should	 not	 be	 unreachable	 for	 them.	 However,	 since	 their	 manufacture	 re-
quires	 immense	amount	of	both	money	and	 time,	pharmaceutical	 companies	 should	
be	encouraged	to	continue	research	by	the	safeguard	of	patent	law.			
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